As pre diabetes is steadily becoming more of a threat, different pharmaceutical brands and conglomerates have taken steps in developing products designed to reduce and control pre diabetes complications from turning into full-blown diabetes cases.
With this current trend, many have come to question the legitimacy of pre diabetes as a condition, going as far as questioning if it is actually a “manufactured” disease.
The sentiments of Colleen Fuller, a Canadian Health Policy Researcher, has caused a domino effect of inquiries and questions, posed in the PharmaWatch Canada website.
“We’re being told that pre-diabetes is an epidemic among people on the verge of developing the real thing [that would be Type 2 Diabetes] and the main reason, according to the popular narrative, is obesity and well, irresponsible sloth,” shares Fuller in the site.
However, as Fuller explains, not everyone is sold out with the operative working concept of pre diabetes, and even notes its too-close-for-comfort “disease-mongering” factor, which is defined by the widening of a diagnostic criteria for a given disorder or disease, in allowing for the expansion of a disorder or disease’s treatment market and marketability.
Given the cost often pegged on pre diabetes treatments, questions pertaining to the actual diagnosis of a pre diabetes condition is one which has to be cleared up. After all, what’s the point of ascribing a certain treatment for a condition which doesn’t necessarily require the said treatment option.
In raising questions about pre diabetes’ “manufactured” disease status, Fuller isn’t questioning the existence of pre diabetes, but is more focused on looking into what pharmaceutical conglomerates have as their respective priorities, given that the emergence of pre diabetes does have a huge market and marketability value.
Bottom line, getting the facts straight before opting for treatments should be at the top of those who are diagnosed as pre diabetic.
